Monoclonal antibodies for COVID-19: What do we know so far?,

According to Dmitry Morozov, BIOCAD’s general director, “The results of clinical trials of the drug, initiated on April 24, demonstrate that levilimab therapy …, According to Dmitry Morozov, BIOCAD’s general director, “The results of clinical trials of the drug, initiated on April 24, demonstrate that levilimab therapy …, Read More

Scroll to Top